Phase 4 N=8 Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism
Mild Hypercortisolism
Primary: A1C Level — 6.2; 6.1375; 6.125 percentage of red blood cells
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=94 Treatment for Endogenous Cushing's Syndrome
Endogenous Cushing's Syndrome
Primary: Normalization in Urinary Free Cortisol in Patients With Endogenous Cushing's Syndrome. — .30 proportion of subjects meeting endpoint — p=0.0154
Phase 2 N=35 Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Cushing's Syndrome
Primary: Percentage of Participants With One or More Adverse Events — 15; 18 Participants
Phase 3 N=50 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Cushing's Syndrome
Primary: Improvement in Diabetes and/or Glucose Intolerance. — 15 participants
Phase 4 N=60 Hydrocortisone Replacement in Patients With Secondary Adrenal Insufficiency (SUPREME CORT)
Adrenal Insufficiency
Primary: Change in Cognition After 10 Weeks of Treatment With a Low Dose of Hydrocortisone Compared to 10 Weeks of Treatment With a High Dose of Hydrocortisone. — -0.41; -0.42…
Phase 3 N=4 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
Cushing's Disease · Cushing's Syndrome
Primary: Number of Participants With Adverse Events — 4 participants
N/A N=22 Value of 25 mcg Cortrosyn Stimulation Test
Adrenal Insufficiency
Primary: Pearson Correlation of the Total Cortisol Levels Between the ITT and CSTs — 0.8; 0.86; 0.93; 0.92 correlation coefficient
Phase 2 N=39 Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men
Cortisol Resistance · Negative Feedback · ACTH
Primary: Proportion of Suppressors After Dexamethasone — 0; 1 Participants — p=0.4872
Phase 3 N=95 Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
Phase 3 N=30 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Cushing's Syndrome
Primary: Number of Participants With Adverse Events — 30 participants
Phase 2 N=8 Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia
Adrenal Insufficiency · Excess Androgen · Congenital Adrenal Hyperplasia (CAH)
Primary: Number of Patients With 17-OHP Levels Equal or Below 1,200 ng/dL at 0700 — 0 Participants
Phase 3 N=122 Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia
Primary: Change From Baseline to 24 Weeks of the Mean of the 24-hour Standard Deviation Score (SDS) Profile for 17-OHP — -0.403; -0.172 Z-score — p==0.5521
Phase 3 N=53 Prevention of Metabolic Complications of Glucocorticoid Excess
Iatrogenic Cushing Disease
Primary: CT Abdomen — 0.08; -0.03 ratio
Phase 3 N=137 A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
Hypercortisolism
Primary: Change in Average 24-hour SBP — -5.56; -2.89 mm Hg — p=0.4160
Phase 2 N=5 Dexamethasone Treatment of Congenital Adrenal Hyperplasia
Adrenal Hyperplasia, Congenital
Primary: Percent Difference in the Mean Log Transformed Area Under the Curve of 17-hydroxyprogesterone Between Regimens — 3.16; 3.91 Log Mean Area Under the Curve — p=0.09
Phase 2 N=14 Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia · 21-Hydroxylase Deficiency · Adrenogenital Syndrome
Primary: Chronocort vs. Cortef Cortisol Concentrations (AUC Over 24 Hours - Time Points 0,.5,1,1.5,2,3,4,5,6,7,8,10,10.5,11, 11.5,12,13,15,17,17.5,18,18.5,19,20,22,24 Post Dose)…
Phase 2 N=68 New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome
Cushing Syndrome · Endocrine Disease
Primary: Sensitivity of Imaging Modalities for the Detection of ACTH-secreting Non-pituitary Tumor in Patients — 96.3; 77.1; 66.7; 100 percentage of patients
Phase 4 N=12 Eszopiclone Treatment & Cortisol Responsivity
Insomnia
Primary: Cortisol Response to the Dex/CRH Test Post-treatment (6 Weeks Oral Drug) — 108.98 nmol/L
Phase 4 N=66 Exploring the Effects of Corticosteroids on the Human Hippocampus
Hydrocortisone · Depression · Healthy Volunteers
Primary: Hippocampal Subfield Activation (Left Hemisphere) — -0.35; 0.03; -0.08; -0.07 Z-Score
Phase 3 N=64 Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency
Adrenal Insufficiency
Primary: Area Under the Concentration Time Curve From Zero to 24 Hours (AUC0-24h) of Total S-cortisol in Plasma After Multiple Doses During Part A — 3962.0; 4879.6 hour*nanomole…
N/A N=21 Hypoglycemia and the Mineralocorticoid Receptor
Hypoglycemia
Primary: Change From Baseline in Cardiovascular Autonomic Function — -16.00; -16.59 ms/mmHg
N/A N=117 Cortisol Response to Moderate and Deep Sedation in Children
Adrenal Insufficiency
Primary: Change From Baseline to Peak Salivary Cortisol Level — 2.9; 4.3; 3.3 Number (ratio of peak to baseline)
Phase 4 N=173 Neurocognitive and Metabolic Effects of Mild Hypothyroidism
Hypothyroidism
Primary: Executive Function — 7.9; 7.5; 8.8 units on a scale
Phase 2 N=15 Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders
Anxiety Disorders
Primary: Drug Acceptability, as Measured by Number of Participants With Dose-limiting Side Effects — 1 Participants
N/A N=7 Adrenal Suppression and Adrenal Recovery Induced by Megestrol Acetate
Adrenal Insufficiency
Primary: Number of Participants With Adrenal Insufficiency — 7 participants
Phase 3 N=51 Open-label Treatment in Cushing's Syndrome
Cushing Syndrome · Cushing Disease
Primary: Proportions of Participants With Mean Urinary Free Cortisol (mUFC) Categorization Based on Upper Limit of Normal (ULN) — 0; 1; 50; 26 Participants
Phase 3 N=55 Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia
Primary: Percentage of Participants Who Were Biochemical Responders at Week 28 — 40.0; 14.3 percentage of participants — p=0.0003
Phase 2 N=48 A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension
Uncontrolled Hypertension
Primary: Number of Participants With Serum Total Cortisol Level Before and After Adrenocorticotropic Hormone (ACTH) Stimulation Test — 0; 0; 26; 15 Participants
Phase 2 N=12 Safety and Efficacy of LCI699 in Cushing's Disease Patients
Cushings Disease · Cushing Disease
Primary: Percentage of Responders to LCI699 Based on the Change in Mean Urinary Free Cortisol (UFC) From Baseline to Week 10 — 100.0 Percentage of participants
Phase 2 N=16 Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH
Endocrine Disease · Adrenal Insufficiency · Congenital Adrenal Hyperplasia
Primary: Pharmacokinetic Profile (Cmax) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia — 601.213 nmol/L